atenolol has been researched along with Melanoma in 2 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Q | 1 |
| Long, J | 1 |
| Hu, L | 1 |
| Chen, Z | 1 |
| Li, Q | 1 |
| Hu, G | 1 |
| Abdel-Maksoud, MS | 1 |
| El-Gamal, MI | 1 |
| Lee, BS | 1 |
| Gamal El-Din, MM | 1 |
| Jeon, HR | 1 |
| Kwon, D | 1 |
| Ammar, UM | 1 |
| Mersal, KI | 1 |
| Ali, EMH | 1 |
| Lee, KT | 1 |
| Yoo, KH | 1 |
| Han, DK | 1 |
| Lee, JK | 1 |
| Kim, G | 1 |
| Choi, HS | 1 |
| Kwon, YJ | 1 |
| Lee, KH | 1 |
| Oh, CH | 1 |
2 other studies available for atenolol and Melanoma
| Article | Year |
|---|---|
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dru | 2020 |
Discovery of New Imidazo[2,1-
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Scr | 2021 |